Author

Gabriela Alperovich 1

1 AbbVie Inc, North Chicago, United States of America

Defining meaningful attributes for the treatment of IBD from patients' perspective

Edouard Louis, Juan Manuel Ramos-Goñi, Jesus Cuervo, Uri Kopylov, Manuel Barreiro de Acosta, Sara McCartney, Greg Rosenfeld, Dominik Bettenworth, Ailsa L Hart, Kerri L. Novak, Xavier Donnet, David Easton, Roberto Saldana, Katja Protze, Eyal Tzur, Gabriela Alperovich, Francesc Casellas Jorda

PYRAMID REGISTRY: LONG-TERM SAFETY OF ADALIMUMAB BY AGE IN PATIENTS WITH CROHN’S DISEASE

Jean-Frederic Colombel, Geert R. D'Haens, Walter Reinisch, Edward V Loftus Jr, Remo Panaccione, Jack Satsangi, Gabriela Alperovich, Sofie Berg, Jasmina Kalabic, Mareike Bereswill, Joel Petersson, Anne M. Robinson

ASSESSMENT OF IMPACT III WELL-BEING DOMAIN SCORES IN ADALIMUMAB-TREATED PAEDIATRIC PATIENTS WITH CROHN'S DISEASE

Amy Grant, Anthony R. Otley, Johanna Caroline Escher, Jeffrey S Hyams, Jen-Fue Maa, Gabriela Alperovich, Andreas Lazar, Anne M. Robinson, Anthony W. Wang, Samantha Eichner

ADALIMUMAB LONG-TERM EFFECTIVENESS IN ADALIMUMAB-NAIVE PATIENTS WITH CROHN'S DISEASE: FINAL DATA FROM PYRAMID REGISTRY

Edward V Loftus Jr, Geert R. D'Haens, Walter Reinisch, Jack Satsangi, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Martha Skup, Joel Petersson, Anne M. Robinson

Translational studies in nonhuman primates and human volunteers support the phase 2 program for ravagalimab in moderately to severely active ulcerative colitis

Stefan Schreiber, Stephen H. Clarke, Bradford L. McRae, Robert G. Caldwell, Ahmed Nader, Gabriela Alperovich, Andreas Lazar

PYRAMID REGISTRY: LONG-TERM SAFETY AND EFFECTIVENESS OF ADALIMUMAB BY BASELINE IMMUNOMODULATOR USE IN PATIENTS WITH CROHN’S DISEASE

Walter Reinisch, Remo Panaccione, Geert R. D'Haens, Edward V Loftus Jr, Jack Satsangi, Jean-Frederic Colombel, Gabriela Alperovich, Sofie Berg, Jasmina Kalabic, Mareike Bereswill, Joel Petersson, Anne M. Robinson

Item 1 - 6 / 6
1